Compare PRAA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAA | BCYC |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.5M | 438.4M |
| IPO Year | N/A | 2019 |
| Metric | PRAA | BCYC |
|---|---|---|
| Price | $16.57 | $6.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $24.33 | $18.73 |
| AVG Volume (30 Days) | ★ 495.0K | 384.4K |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,161,679,000.00 | $28,339,000.00 |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $12.29 | $6.03 |
| 52 Week High | $23.97 | $21.50 |
| Indicator | PRAA | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 47.65 |
| Support Level | $15.70 | $6.03 |
| Resistance Level | $16.57 | $7.83 |
| Average True Range (ATR) | 0.67 | 0.43 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 94.44 | 46.67 |
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.